Pharmacy News EU

9 February 2010 – US biotechnology company Cara Therapeutics Inc reported yesterday encouraging data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845.The 46-patient, Phase II, multi-centre, double-blind, placebo-controlled study was conducted at eight hospitals in the US and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted [...]

SHELTON, Conn., Feb. 8 /PRNewswire/ Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women [...]

Jan 28, 2010 (Datamonitor via COMTEX) Roxane Laboratories, a subsidiary of Boehringer Ingelheim, has announced the new drug application, or NDA, approval of morphine sulfate oral solution CII, 100mg/5ml, 30ml and 120ml bottles by the FDA.According to the company, the morphine sulfate oral solution product is indicated for the relief of moderate to severe acute [...]

WASHINGTON-The Food and Drug Administration says it has confirmed the safety of a widely-used formulation of morphine that was previously unapproved.The agency approved Roxane Laboratories’ Morphine Sulfate oral solution for patients with moderate to severe chronic pain.Doctors have used the formulation for years, but it was previously not approved by FDA regulators.In March, the FDA [...]

FDA Approves Morphine Sulfate Oral Solution for Relief of Acute and Chronic PainTue, 26 Jan 2010 09:17:00 -0600The U.S. Food and Drug Administration today approved Morphine Sulfate Oral Solution for the relief of moderate to severe, acute and chronic pain in opioid-tolerant patients. This medicine will be available in 100 milligrams per 5 mL or [...]

2010 JAN 11 – (NewsRx.com) "When conventional multimodal analgesic therapy is unsuccessful, more aggressive analgesic treatments are required for patients with intractable chronic pain (see also Morphine Therapy). Despite extensive clinical experience with implanted morphine pumps, there is still controversy regarding the psychosocial effects of this invasive analgesic therapy," scientists in Padua, Italy report."In [...]

2009 DEC 25 – (NewsRx.com) "The pharmacokinetics of a novel sustained-release oral formulation of morphine have been evaluated (see also Pharmacokinetics). The formulation consisted of tablets containing a morphine-Eudragit L complex (MEC) which had shown good sustained-release properties in previous in vitro dissolution studies," scientists writing in the journal Pharmazie report."MEC tablets were [...]

"The pharmacokinetics of a novel sustained-release oral formulation of morphine have been evaluated. The formulation consisted of tablets containing a morphine-Eudragit L complex (MEC) which had shown good sustained-release properties in previous in vitro dissolution studies," scientists writing in the journal Pharmazie report (see also Pharmacokinetics)."MEC tablets were administered orally to beagle dogs and [...]